ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson’s Disease
Open accessAbstract
Background: Parkinson’s disease (PD) is the second commonest neurodegenerative disease. The genetic basis of PD is indisputable. Both ADORA2A rs5760423 and CYP1A2 rs762551 have been linked to PD, to some extent, but the exact role of those polymorphisms in PD remains controversial. Objective: We assessed the role of ADORA2A rs5760423 and CYP1A2 rs762551 on PD risk. Methods: We genotyped 358 patients with PD and 358 healthy controls for ADORA2A rs5760423 and CYP1A2 rs762551. We also merged and meta-analyzed our data with data from previous studies, regarding these two polymorphisms and PD. Results: No significant association with PD was revealed (p > 0.05), for either ADORA2A rs5760423 or CYP1A2 rs762551, in any of the examined genetic model of inheritance. In addition, results from meta-analyses yield negative results. Conclusions: Based on our analyses, it appears rather unlikely that ADORA2A rs5760423 or CYP1A2 rs762551 is among the major risk factors for PD, at least in Greek patients with PD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increase in life expectancy is one factor that has led to an increase in the number of Alzheimer's disease cases worldwide.
“The increase in life expectancy is one of the factors that has led to an increase in the number of AD cases worldwide [3,4].”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689 · see citing works
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · see citing works
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · see citing works
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415 · see citing works
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · see citing works
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K., Holloway, R. G., Kieburtz, K. D., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A. D., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,479 · see citing works
SNPStats: a web tool for the analysis of association studies
Solé, X., Guinó, E., Valls, J., Iniesta, R., & Moreno, V. R. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl268 · Cited by 2,011 · see citing works
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,837 · see citing works
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410 · see citing works
Skol, A. D., Scott, L. J., Abecasis, G. R., & Boehnke, M. (2006) · Nature Genetics · doi:10.1038/ng1706 · Cited by 1,286 · see citing works
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190 · see citing works
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050 · see citing works
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972 · see citing works
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. E. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 772 · see citing works
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751 · see citing works
Systematic review of incidence studies of Parkinson's disease
Twelves, D., Perkins, K. S. M., & Counsell, C. E. (2002) · Movement Disorders · doi:10.1002/mds.10305 · Cited by 619 · see citing works
Chen, J., Xu, K., Petzer, J. P., Staal, R. G. W., Xu, Y., Beilstein, M. A., Sonsalla, P. K., Castagnoli, K., Castagnoli, N. J., & Schwarzschild, M. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 608 · see citing works
Adenosine A2A receptors and basal ganglia physiology
Schiffmann, S. N., Fisone, G., Moresco, R. M., Cunha, R. A., & Ferré, S. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.05.001 · Cited by 393 · see citing works
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Bandrés‐Ciga, S., Díez-Fairén, M., Kim, J. J., & Singleton, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104782 · Cited by 368 · see citing works
Genetics of Parkinson's disease
Lill, C. M. (2016) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2016.11.001 · Cited by 362 · see citing works
Association between A2a receptor gene polymorphisms and caffeine-induced anxiety
Alsene, K., Deckert, J., Sand, P., & de Wit, H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300232 · Cited by 334 · see citing works
The neuroprotective effects of caffeine in neurodegenerative diseases
Kolahdouzan, M., & Hamadeh, M. J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12684 · Cited by 304 · see citing works
Rétey, J. V., Adam, M., Khatami, R., Luhmann, U. F. O., Jung, H. H., Berger, W., & Landolt, H.-P. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100102 · Cited by 278 · see citing works
Tan, E., Tan, C. I. C., Fook-Chong, S. M. C., Lum, S. Y., Chai, A., Chung, H., Shen, H., Zhao, Y., Teoh, M. L., Yih, Y., et al. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.07.006 · Cited by 186 · see citing works
Pathophysiology and Diagnosis of ALS: Insights from Advances in Neurophysiological Techniques
van den Bos, M. A. J., Geevasinga, N., Higashihara, M., Menon, P., & Vucic, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112818 · Cited by 152 · see citing works
Advances in Parkinson’s Disease: 200 Years Later
del Rey, N. L., Quiroga‐Varela, A., Garbayo, E., Carballo‐Carbajal, I., Fernández‐Santiago, R., Monje, M. H. G., Trigo‐Damas, I., Blanco‐Prieto, M. J., & Blesa, J. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00113 · Cited by 146 · see citing works
Morelli, M., Paolo, T. D., Wardas, J., Calon, F., Xiao, D., & Schwarzschild, M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.07.001 · Cited by 145 · see citing works
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease
Popat, R. A., Eeden, S. K. V. D., Tanner, C. M., Kamel, F., Umbach, D. M., Marder, K. S., Mayeux, R. P., Ritz, B. R., Ross, G. W., Petrovitch, H., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03353.x · Cited by 119 · see citing works
H. pylori and Parkinson’s disease: Meta-analyses including clinical severity
Dardiotis, E., Tsouris, Z., Mentis, A. A., Siokas, V., Michalopoulou, A., Sokratous, M., Dastamani, M., Bogdanos, D. P., Deretzi, G., & Kountouras, J. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.09.039 · Cited by 115 · see citing works
Self-citationDardiotis, E., Xiromerisiou, G., Hadjichristodoulou, C. S., Tsatsakis, A. M., Wilks, M. F., & Hadjigeorgiou, G. M. (2013) · Toxicology · doi:10.1016/j.tox.2012.12.016 · Cited by 112 · see citing works
Self-citationKoonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100 · see citing works
Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Fujimaki, M., Saiki, S., Li, Y., Kaga, N., Taka, H., Hatano, T., Ishikawa, K., Oji, Y., Mori, A., Okuzumi, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004888 · Cited by 100 · see citing works
Docea, A. O., Vassilopoulou, L., Fragou, D., Arsene, A. L., Fenga, C., Kovatsi, L., Petrakis, D., Rakitskii, V. N., Nosyrev, A. E., Izotov, B. N., et al. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.05.007 · Cited by 82 · see citing works
Self-citationHorgusluoglu, E., Nho, K. T., Risacher, S. L., Kim, S., Foroud, T., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.010 · Cited by 78 · see citing works
Stiborová, M., Levová, K., Bárta, F., Shi, Z., Frei, E., Schmeiser, H. H., Nebert, D. W., Phillips, D. H., & Arlt, V. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr306 · Cited by 67 · see citing works
Sridhar, J., Goyal, N., Liu, J., & Foroozesh, M. K. (2017) · Molecules · doi:10.3390/molecules22071143 · Cited by 67 · see citing works
Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers
Tan, E., Chua, E., Fook-Chong, S. M. C., Teo, Y., Yih, Y., Tan, L. C. S., & Zhao, Y. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f09265 · Cited by 62 · see citing works
Liu, C., Liu, Z., Zhang, Z., Li, Y., Fang, R., Li, F., & Zhang, J. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00091 · Cited by 56 · see citing works
Parkinson's disease and pesticides: Are microRNAs the missing link?
Aloizou, A., Siokas, V., Sapouni, E.-M., Sita, N., Liampas, I., Brotis, A. G., Rakitskii, V. N., Burykina, T. I., Aschner, M., Bogdanos, D. P., et al. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.140591 · Cited by 53 · see citing works
Self-citationPalacios, N., Weisskopf, M. G., Simon, K., Gao, X., Schwarzschild, M. A., & Ascherio, A. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.02.012 · Cited by 51 · see citing works
Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2
Chuang, Y., Lill, C. M., Lee, P., Hansen, J., Lassen, C. F., Bertram, L., Greene, N., Sinsheimer, J. S., & Ritz, B. R. (2016) · Neuroepidemiology · doi:10.1159/000450855 · Cited by 48 · see citing works
Organochlorine pesticide levels in Greek patients with Parkinson’s disease
Dardiotis, E., Aloizou, A., Sakalakis, E., Siokas, V., Koureas, M., Xiromerisiou, G., Petinaki, E. A., Wilks, M. F., Tsatsakis, A. M., Hadjichristodoulou, C. S., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.03.011 · Cited by 47 · see citing works
Self-citationCoffee, caffeine‐related genes, and Parkinson's disease: A case–control study
Facheris, M., Schneider, N. K., Lesnick, T. G., de Andrade, M., Cunningham, J. M., Rocca, W. A., & Maraganore, D. M. (2008) · Movement Disorders · doi:10.1002/mds.22247 · Cited by 41 · see citing works
Rieck, M., Schuh, A. F. S., Callegari-Jacques, S. M., Altmann, V., Medeiros, M. S., Rieder, C. R. D. M., & Hutz, M. H. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.23 · Cited by 39 · see citing works
BDNF rs6265 (Val66Met) Polymorphism as a Risk Factor for Blepharospasm
Siokas, V., Kardaras, D., Aloizou, A., Asproudis, I., Boboridis, K. G., Papageorgiou, E., Hadjigeorgiou, G. M., Tsironi, E. E., & Dardiotis, E. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8519-5 · Cited by 33 · see citing works
Self-citationThe Role of TOR1A Polymorphisms in Dystonia: A Systematic Review and Meta-Analysis
Siokas, V., Dardiotis, E., Tsironi, E. E., Tsivgoulis, G. K., Rikos, D., Sokratous, M., Koutsias, S. G., Paterakis, K. N., Deretzi, G., & Hadjigeorgiou, G. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169934 · Cited by 32 · see citing works
Self-citationCaffeine; the Forgotten Potential for Parkinson's Disease
Negida, A., Elfil, M., Attia, A., Farahat, E. S., Gabr, M., Essam, A., Attia, D. H., & Ahmed, H. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161107091149 · Cited by 27 · see citing works
Kim, I. Y., O’Reilly, É. J., Hughes, K. C., Gao, X., Schwarzschild, M. A., McCullough, M. L., Hannan, M. T., Betensky, R. A., & Ascherio, A. (2018) · Movement Disorders · doi:10.1002/mds.27279 · Cited by 24 · see citing works
Dardiotis, E., Siokas, V., Zafeiridis, T., Paterakis, K. N., Tsivgoulis, G. K., Dardioti, M., Grigoriadis, S., Simeonidou, C., Deretzi, G., Zintzaras, E., et al. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8429-3 · Cited by 23 · see citing works
Self-citationDardiotis, E., Rikos, D., Siokas, V., Aloizou, A., Tsouris, Z., Sakalakis, E., Brotis, A. G., Bogdanos, D. P., & Hadjigeorgiou, G. M. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1750388 · Cited by 23 · see citing works
Self-citationLack of Association of the rs11655081 ARSG Gene with Blepharospasm
Siokas, V., Kardaras, D., Aloizou, A., Asproudis, I., Boboridis, K. G., Papageorgiou, E., Spandidos, D. A., Tsatsakis, A. M., Tsironi, E. E., & Dardiotis, E. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1255-3 · Cited by 19 · see citing works
Self-citationCYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis
Siokas, V., Karampinis, E., Aloizou, A., Mentis, A. A., Liakos, P., Papadimitriou, D. A., Liampas, I., Nasios, G., Bogdanos, D. P., Hadjigeorgiou, G. M., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04535-x · Cited by 17 · see citing works
Self-citationMultiple Sclerosis: Shall We Target CD33?
Siokas, V., Tsouris, Z., Aloizou, A., Bakirtzis, C., Liampas, I., Koutsis, G., Anagnostouli, M. C., Bogdanos, D. P., Grigoriadis, N., Hadjigeorgiou, G. M., et al. (2020) · Genes · doi:10.3390/genes11111334 · Cited by 15 · see citing works
Self-citationCYP1A2 rs762551 and ADORA2A rs5760423 Polymorphisms in Patients with Blepharospasm
Siokas, V., Kardaras, D., Aloizou, A., Liampas, I., Papageorgiou, E., Drakoulis, N., Tsatsakis, A. M., Mitsias, P. D., Hadjigeorgiou, G. M., Tsironi, E. E., et al. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01553-4 · Cited by 13 · see citing works
Self-citationHill‐Burns, E. M., Hamza, T. H., Zabetian, C. P., Factor, S. A., & Payami, H. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03464.x · Cited by 10 · see citing works
CD14 C260T promoter polymorphism and the risk of cerebrovascular diseases: a meta-analysis
Banerjee, I. (2009) · Journal of Applied Genetics · doi:10.1007/bf03195667 · Cited by 6 · see citing works
Parkinson disease genetics: too early to predict progression?
Kuhlenbäumer, G., & Berg, D. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0264-3 · Cited by 6 · see citing works
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives
Semwal, P., Painuli, S., Abu-Izneid, T., Rauf, A., Sharma, A., Daştan, S. D., Kumar, M., Alshehri, M. M., Taheri, Y., Das, R., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1035441 · Cited by 195 · see citing works
Neuropharmacological Effects of Quercetin: A Literature-Based Review
Islam, M. S., Quispe, C., Hossain, R., Islam, M. T., Al-Harrasi, A., Al-Rawahi, A., Martorell, M., Mamurova, A., Seilkhan, A., Altybaeva, N., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665031 · Cited by 165 · see citing works
Self-citationSharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125 · see citing works
“The increase in life expectancy is one of the factors that has led to an increase in the number of AD cases worldwide [3,4].”
BackgroundRecent advances in the therapeutic potential of emodin for human health
Sharifi‐Rad, J., Herrera‐Bravo, J., Kamiloğlu, S., Petroni, K., Mishra, A. P., Monserrat-Mesquida, M., Sureda, A., Martorell, M., Dossymbetova, S., Yessimsiitova, Z. B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113555 · Cited by 100 · see citing works
Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation
Iqbal, M. J., Javed, Z., Herrera‐Bravo, J., Sadia, H., Anum, F., Raza, S., Tahir, A., Shahwani, M. N., Sharifi‐Rad, J., Călina, D. C., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02777-7 · Cited by 77 · see citing works
Udaya Rajesh, R., & Sangeetha, D. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104881 · Cited by 77 · see citing works
Angelopoulou, E., Paudel, Y. N., Papageorgiou, S. G., & Piperi, C. (2022) · Brain Sciences · doi:10.3390/brainsci12020175 · Cited by 73 · see citing works
Amin, R., Quispe, C., Docea, A. O., Ydyrys, A., Kulbayeva, M., Durna Daştan, S., Calina, D., & Sharifi-Rad, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105376 · Cited by 74 · see citing works
Self-citationChaudhary, P., Mitra, D., MOHAPATRA, P. K. D., Docea, A. O., Myo, E. M., Janmeda, P., Martorell, M., Iriti, M., Ibrayeva, M., Sharifi‐Rad, J., et al. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104680 · Cited by 60 · see citing works
Self-citationIslam, M. T., Quispe, C., El‐Kersh, D. M., Shill, M. C., Bhardwaj, K., Bhardwaj, P., Sharifi‐Rad, J., Martorell, M., Hossain, R., Al‐Harrasi, A., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6349041 · Cited by 59 · see citing works
Self-citationNeurobiological Promises of the Bitter Diterpene Lactone Andrographolide
Hossain, R., Quispe, C., Herrera‐Bravo, J., Beltrán, J. F., Islam, M. T., Shaheen, S., Martins, N. A., Martorell, M., Kumar, M., Sharifi‐Rad, J., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3079577 · Cited by 27 · see citing works
Unlocking the adenosine receptor mechanism of the tumour immune microenvironment
Han, Y., Dong, C., Hu, M., Wang, X., & Wang, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434118 · Cited by 26 · see citing works
Siokas, V., Aloizou, A., Liampas, I., Bakirtzis, C., Tsouris, Z., Sgantzos, M. N., Liakos, P., Bogdanos, D. P., Hadjigeorgiou, G. M., & Dardiotis, E. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13538 · Cited by 24 · see citing works
Self-citationPrasher, P., Sharma, M., Sharma, A. K., Sharifi‐Rad, J., Călina, D. C., Hano, C., & Cho, W. C. S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114332 · Cited by 23 · see citing works
Therapeutic application of rTMS in neurodegenerative and movement disorders: A review
Pateraki, G., Anargyros, K., Aloizou, A., Siokas, V., Bakirtzis, C., Liampas, I., Tsouris, Z., Ziogka, P., Sgantzos, M. N., Folia, V., et al. (2021) · Journal of Electromyography and Kinesiology · doi:10.1016/j.jelekin.2021.102622 · Cited by 21 · see citing works
Self-citationSiokas, V., Mouliou, D. S., Liampas, I., Aloizou, A., Folia, V., Zoupa, E., Papadimitriou, A., Lavdas, E., Bogdanos, D. P., & Dardiotis, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214400 · Cited by 16 · see citing works
Self-citationBarati, S., Fabrizio, C., Strafella, C., Cascella, R., Caputo, V., Megalizzi, D., Peconi, C., Mela, J., Colantoni, L., Caltagirone, C., et al. (2022) · Genes · doi:10.3390/genes13081498 · Cited by 14 · see citing works
CD33 rs3865444 as a risk factor for Parkinson’s disease
Siokas, V., Arseniou, S., Aloizou, A., Tsouris, Z., Liampas, I., Sgantzos, M. N., Liakos, P., Bogdanos, D. P., Hadjigeorgiou, G. M., & Dardiotis, E. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135709 · Cited by 14 · see citing works
Self-citationPharmacological update on Benincasa Hispida (Thunb.): A review
Singh, S., Gohil, K. J., & Singh, M. P. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100478 · Cited by 13 · see citing works
Victor, A. K., Hedgecock, T., Donaldson, M., Johnson, D. L., Rand, C. M., Weese‐Mayer, D. E., & Reiter, L. T. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1090084 · Cited by 11 · see citing works
Fan, H.-H., Li, B., Wu, K.-Y., Yan, H.-D., Gu, M.-J., Yao, X., Dong, H., Zhang, X., & Zhu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888942 · Cited by 11 · see citing works
D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia
Florio, E., Serra, M., Lewis, R. G., Kramár, E. A., Freidberg, M. D., Wood, M. A., Morelli, M., & Borrelli, E. (2022) · iScience · doi:10.1016/j.isci.2022.105263 · Cited by 11 · see citing works
Sharifi‐Rad, J., Almarhoon, Z. M., Adetunji, C. O., Michael, O. S., Chandran, D., Radha, R., Sharma, N., Kumar, M., & Călina, D. C. (2022) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.22.02946-7 · Cited by 7 · see citing works
Neurocognitive Impairment and Social Cognition in Parkinson’s Disease Patients
Doskas, T. K., Vadikolias, Κ., Ntoskas, K. T., Vavougios, G. D., Tsiptsios, D., Stamati, P., Liampas, I., Siokas, V., Messinis, L., Nasios, G., et al. (2024) · Neurology International · doi:10.3390/neurolint16020032 · Cited by 3 · see citing works
Self-citationReplication of chromosomal loci involved in Parkinson’s disease: A quantitative synthesis of GWAS
Rikos, D., Siokas, V., Burykina, T. I., Drakoulis, N., Dardiotis, E., & Zintzaras, E. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.10.008 · Cited by 2 · see citing works
Self-citationChen, K., Hao, W., Ji, Y., Xu, B., Lu, L., Zhang, R., Lu, Y., Chen, K., Wang, F., Hu, X., et al. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108218 · Cited by 1 · see citing works
Wu, Q., Wang, M., Chen, W., Wang, K., & Wang, Y. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.104279 · Cited by 1 · see citing works
O USO DA CAFEÍNA NA TERAPIA NUTRICIONAL DE PACIENTE COM DEPRESSÃO
dos Anjos, R. S. G., & de Albuquerque, M. O. P. C. (2023) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v4i1.2584
Amjad, G., Saif, R., & Hussain, M. G. (2026) · Futuristic Biotechnology · doi:10.54393/fbt.v6i1.225
- Authors
- Siokas, V., Aloizou, A.-M., Tsouris, Z., Liampas, I., Liakos, P., Calina, D., Docea, A. O., Tsatsakis, A., Bogdanos, D. P., Hadjigeorgiou, G. M., & Dardiotis, E.
- Affiliations
- University of Thessaly (GR)
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
- University of Medicine and Pharmacy of Craiova (RO)
- University of Crete (GR)
- Corresponding author
- Dardiotis, Efthimios
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-01-20
- Volume
- 10
- Issue
- 3
- Pages
- 381
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7864159
- OpenAlex
- W3123965594
- Cited by
- 29
- References
- 62
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 5 · 2022: 13 · 2021: 6
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
- Funders
- This study was supported in part by a research grant from the Research Committee of the University of Thessaly, Greece (code: 5287).” (code: 5287)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, genetic polymorphism, genetic risk factors, adenosine A2A receptor, CYP1A2, meta-analysis, Greek patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
